- Cancer Biology
- Chromatography & Mass Spectrometry
- Contract Research
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & Rapid Micro Methods (RMMs)
- Process Analytical Technology (PAT) & Quality by Design (QbD)
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
- Latest News
- Contact us
Pharma industry news
Posted on: 30 October 2014 | Source: Bristol-Myers Squibb
Phase 2 objective response rate and survival data for Opdivo (nivolumab) in heavily pre-treated advanced squamous cell non-small cell lung cancer to be presented at the 2014 Chicago Multidisciplinary Symposium on Thoracic Oncology...
Posted on: 30 October 2014 | Source: British Generic Manufacturers Association
Auditing will be a key theme of the British Generic Manufacturers Association’s (BGMA) next Quality Forum meeting on Wednesday, November 12th which is run in partnership with the MHRA...
Lilly shares technology insights to increase supply of medicines for multidrug-resistant tuberculosis
Posted on: 30 October 2014 | Source: Eli Lilly and Company
Eli Lilly and Company published details of its long-standing technology transfer program to increase the global supply of medicines for multidrug-resistant tuberculosis (MDR-TB)...
Merck Forms a Scientific Partnership with Kenya Medical Research Institute (KEMRI) as part of its Capacity Advancement Program in Africa
Posted on: 29 October 2014 | Source: Merck
Merck announced today the signature of a memorandum of understanding with Kenya Medical Research Institution (KEMRI) for a scientific partnership aimed at contributing to the country’s social and economic development. The partnership will cover research and development projects, programs and activities focused on malaria and schistosomiasis, as well as related co-infections...
Posted on: 29 October 2014 | Source: GBI Research
The global Non-Hodgkin Lymphoma (NHL) treatment market will increase in value from $5.6 billion in 2013 to $9.2 billion by 2020, representing a Compound Annual Growth Rate (CAGR) of 7.4%, says business intelligence provider GBI Research...
Posted on: 29 October 2014 | Source: Eli Lilly and Company
Eli Lilly and Company (LLY) will participate in the Credit Suisse 2014 Healthcare Conference at the Arizona Biltmore in Phoenix, AZ, on Wednesday, November 12, 2014. Jeffrey Simmons, Senior Vice President and President, Elanco Animal Health, will make a formal presentation at 1:30 p.m. EST...
Posted on: 29 October 2014 | Source: Sanofi
Sanofi's Board of Directors have decided unanimously to remove Christopher A. Viehbacher as Chief Executive Officer of Sanofi. As a consequence Christopher A. Viehbacher resigned as a director of Sanofi...
Posted on: 28 October 2014 | Source: Eli Lilly &Company
Eli Lilly and Company LLY, -2.58% issued the following statement in response to a judge's ruling that the punitive damages awarded in the case of Terrence Allen, et al. v. Takeda Pharmaceuticals North America, Inc., et al, No. 6:12-cv-00064 be reduced...
Posted on: 28 October 2014 | Source: Boehringer Ingelheim
Global top 20 pharma company streamlines R&D IT with cross-domain platform...
Bristol-Myers Squibb enters into agreement that provides an exclusive option to acquire F-star Alpha Ltd. and its novel HER2-targeted therapy
Posted on: 28 October 2014 | Source: Bristol-Myers Squibb Company
Bristol-Myers Squibb Company and F-star Alpha Ltd. announced that the companies, together with the F-star Alpha Ltd. shareholders, have entered into an agreement that provides Bristol-Myers Squibb the exclusive option to acquire F-star Alpha Ltd, and gain worldwide rights to its lead asset FS102...
Posted on: 28 October 2014 | Source: Distributed by APO (African Press Organization) on behalf of SkyVision Global Networks Ltd
The fund will be used to cover expenses and the needs of Ebola patients and affected families...
First patient included in phase ll study of BUPI, a novel topical formulation for treatment of oral pain
Posted on: 28 October 2014 | Source: Moberg Pharma
Moberg Pharma AB announced that the first patient has been included in a randomized controlled phase ll study with BUPI, a novel topical formulation for the treatment of oral pain...